- Home
- GIGM vs PPBT Comparison
GIGM vs PPBT Comparison
Compare GIGM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- PPBT
- Stock Information
- Founded
- GIGM 1998
- PPBT 2010
- Country
- GIGM Taiwan
- PPBT Israel
- Employees
- GIGM N/A
- PPBT N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- PPBT Health Care
- Exchange
- GIGM Nasdaq
- PPBT Nasdaq
- Market Cap
- GIGM 17.0M
- PPBT 2.1M
- IPO Year
- GIGM 2000
- PPBT N/A
- Fundamental
- Price
- GIGM $1.75
- PPBT $0.59
- Analyst Decision
- GIGM
- PPBT Strong Buy
- Analyst Count
- GIGM 0
- PPBT 1
- Target Price
- GIGM N/A
- PPBT $33.00
- AVG Volume (30 Days)
- GIGM 22.4K
- PPBT 2.9M
- Earning Date
- GIGM 10-29-2025
- PPBT 11-14-2025
- Dividend Yield
- GIGM N/A
- PPBT N/A
- EPS Growth
- GIGM N/A
- PPBT N/A
- EPS
- GIGM N/A
- PPBT N/A
- Revenue
- GIGM $3,250,000.00
- PPBT N/A
- Revenue This Year
- GIGM N/A
- PPBT N/A
- Revenue Next Year
- GIGM N/A
- PPBT N/A
- P/E Ratio
- GIGM N/A
- PPBT N/A
- Revenue Growth
- GIGM N/A
- PPBT N/A
- 52 Week Low
- GIGM $1.30
- PPBT $0.53
- 52 Week High
- GIGM $1.89
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- GIGM 59.78
- PPBT 14.50
- Support Level
- GIGM $1.61
- PPBT $0.53
- Resistance Level
- GIGM $1.89
- PPBT $0.63
- Average True Range (ATR)
- GIGM 0.09
- PPBT 0.13
- MACD
- GIGM 0.01
- PPBT -0.03
- Stochastic Oscillator
- GIGM 66.64
- PPBT 2.83
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.